[HTML][HTML] Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis
Background & Aims MRI-based corrected T1 (cT1) is a non-invasive method to grade the
severity of steatohepatitis and liver fibrosis. We aimed to identify genetic variants influencing …
severity of steatohepatitis and liver fibrosis. We aimed to identify genetic variants influencing …
[HTML][HTML] Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease
M Pavlides, R Banerjee, J Sellwood, CJ Kelly… - Journal of …, 2016 - Elsevier
Background & Aims Multiparametric magnetic resonance (MR) imaging has been
demonstrated to quantify hepatic fibrosis, iron, and steatosis. The aim of this study was to …
demonstrated to quantify hepatic fibrosis, iron, and steatosis. The aim of this study was to …
NASH drug treatment development: challenges and lessons
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver
disease worldwide. Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver …
disease worldwide. Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver …
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial
TG Simon, RM Wilechansky, S Stoyanova, A Grossman… - JAMA, 2024 - jamanetwork.com
Importance Aspirin may reduce severity of metabolic dysfunction–associated steatotic liver
disease (MASLD) and lower the incidence of end-stage liver disease and hepatocellular …
disease (MASLD) and lower the incidence of end-stage liver disease and hepatocellular …
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
V Ratziu, SA Harrison, V Loustaud-Ratti, C Bureau… - Journal of …, 2023 - Elsevier
Background & Aims The LIVIFY trial investigated the safety, tolerability, and efficacy of
vonafexor, a second-generation, non-bile acid farnesoid X receptor agonist in patients with …
vonafexor, a second-generation, non-bile acid farnesoid X receptor agonist in patients with …
Diagnosis and management of non-alcoholic fatty liver disease
E Jennison, J Patel, E Scorletti… - Postgraduate medical …, 2019 - academic.oup.com
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in
Western industrialised countries. The prevalence of NAFLD is increasing in parallel with the …
Western industrialised countries. The prevalence of NAFLD is increasing in parallel with the …
Quantification of liver fibrosis at T1 and T2 mapping with extracellular volume fraction MRI: preclinical results
JA Luetkens, S Klein, F Träber, FC Schmeel… - Radiology, 2018 - pubs.rsna.org
Purpose To evaluate MRI T1 and T2 mapping with calculation of extracellular volume (ECV)
for diagnosis and grading of liver fibrosis. Materials and Methods Different grades of fibrosis …
for diagnosis and grading of liver fibrosis. Materials and Methods Different grades of fibrosis …
[PDF][PDF] CRAF methylation by PRMT6 regulates aerobic glycolysis–driven hepatocarcinogenesis via ERK‐dependent PKM2 nuclear relocalization and activation
Background and Aims Most tumor cells use aerobic glycolysis (the Warburg effect) to
support anabolic growth and promote tumorigenicity and drug resistance. Intriguingly, the …
support anabolic growth and promote tumorigenicity and drug resistance. Intriguingly, the …
Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis
Introduction Late stage clinical trials in non-alcoholic steatohepatitis (NASH) are currently
required by the FDA to use liver biopsy as a primary endpoint. The well-reported limitations …
required by the FDA to use liver biopsy as a primary endpoint. The well-reported limitations …